Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic Acquires Rights to Scoliosis Prognostic Test

NEW YORK (GenomeWeb News) - Transgenomic today said that it has signed a definitive agreement to acquire the global rights to a multi-gene prognostic test for scoliosis from Axial Biotech.

The Omaha, Neb.-based molecular diagnostics firm bought the rights to Axial's ScoliScore Adolescent Idiopathic Scoliosis (AIS) Prognostic Test for $4.4 million in cash. The clinically validated and commercially available test uses saliva as a sample to look for multiple genes that provide a "highly accurate" assessment of the likelihood of spinal curve progression for children diagnosed with AIS, said Transgenomic.

"The ScoliScore Test identifies, with a high degree of accuracy, those individuals who are unlikely to progress to a point where surgery is needed, which can significantly reduce their radiation exposure from repeated x-ray monitoring," Transgenomic CEO Craig Tuttle said in a statement.

He noted that he expects the test to contribute positively to the firm's earnings by the end of 2012, excluding any acquisition related charges.

The firms did not disclose sales figures for the test, but Transgenomic said that it provides access to a market estimated at 400,000 patients in the US.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.